Subasumstat

N/A

Report date: 2024/02/22 16:34:36
NMEFirst In Class

Base Information

Drug NameSubasumstat
Drug Alias NameTAK-981
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSUMO-Activating Enzyme E1 inhibitors
TargetsSUMO-Activating Enzyme E1
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsHematologic Neoplasms +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTakeda (China) International Trading Co LtdPresage Biosciences IncTakeda Pharmaceutical Co Ltd +[4] 
Inactive CompaniesLyophilization Services Of New England Inc
Active IndicationsSolid tumoursHead and Neck NeoplasmsLymphoma, Non-Hodgkin
Inactive IndicationsUterine Cervical NeoplasmsHematologic NeoplasmsMultiple Myeloma +[5] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG